全文获取类型
收费全文 | 32120篇 |
免费 | 3027篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 248篇 |
儿科学 | 1042篇 |
妇产科学 | 1215篇 |
基础医学 | 4280篇 |
口腔科学 | 654篇 |
临床医学 | 4356篇 |
内科学 | 6697篇 |
皮肤病学 | 393篇 |
神经病学 | 2592篇 |
特种医学 | 1000篇 |
外国民族医学 | 1篇 |
外科学 | 3453篇 |
综合类 | 570篇 |
一般理论 | 54篇 |
预防医学 | 3949篇 |
眼科学 | 456篇 |
药学 | 2484篇 |
中国医学 | 14篇 |
肿瘤学 | 1733篇 |
出版年
2022年 | 243篇 |
2021年 | 509篇 |
2020年 | 358篇 |
2019年 | 582篇 |
2018年 | 650篇 |
2017年 | 491篇 |
2016年 | 522篇 |
2015年 | 553篇 |
2014年 | 829篇 |
2013年 | 1133篇 |
2012年 | 1709篇 |
2011年 | 1710篇 |
2010年 | 918篇 |
2009年 | 890篇 |
2008年 | 1527篇 |
2007年 | 1740篇 |
2006年 | 1628篇 |
2005年 | 1622篇 |
2004年 | 1542篇 |
2003年 | 1505篇 |
2002年 | 1390篇 |
2001年 | 799篇 |
2000年 | 850篇 |
1999年 | 755篇 |
1998年 | 374篇 |
1997年 | 316篇 |
1996年 | 326篇 |
1995年 | 302篇 |
1994年 | 273篇 |
1993年 | 260篇 |
1992年 | 566篇 |
1991年 | 575篇 |
1990年 | 557篇 |
1989年 | 570篇 |
1988年 | 502篇 |
1987年 | 519篇 |
1986年 | 462篇 |
1985年 | 437篇 |
1984年 | 392篇 |
1983年 | 324篇 |
1982年 | 284篇 |
1981年 | 222篇 |
1980年 | 200篇 |
1979年 | 300篇 |
1978年 | 299篇 |
1977年 | 212篇 |
1976年 | 216篇 |
1975年 | 211篇 |
1974年 | 228篇 |
1972年 | 209篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
5.
6.
7.
8.
Facundo Davaro Jacob Roberts Allison May Coleman McFerrin Sameer Siddiqui Zachary Hamilton 《Journal of robotic surgery》2020,14(3):447-454
Partial nephrectomy is the mainstay of treatment for localized kidney cancer. A proportion of patients are upstaged post-operatively to locally advanced di 相似文献
9.
Stanislas Grassin‐Delyle Michaela Semeraro Frantz Foissac Naim Bouazza Haleema Shakur‐Still Ian Roberts Jean‐Marc Treluyer Saïk Urien 《Fundamental & clinical pharmacology》2019,33(6):670-678
Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss and death due to bleeding after trauma and post‐partum haemorrhage. One key issue for treatment success is early administration. While usually given intravenously, oral and intramuscular use would be useful in specific circumstances. Therefore, an understanding of TXA pharmacokinetics when given via different routes is valuable. The aim of this study was to perform an individual participant data meta‐analysis of pharmacokinetic studies with TXA given to healthy volunteers via different routes. We searched the following databases: PubMed, Web of Science, Wiley Online Library, Elsevier Science Direct and J‐STAGE. Individual subject data were extracted when available, otherwise arithmetic means were used. A population pharmacokinetic model was developed using nonlinear mixed effect modelling. Seven studies were included in the analysis with data from 10 patients for the IV route, six patients for the IM route and 114 patients for the oral route. The pharmacokinetics was ascribed to a two‐compartment model, and the main covariate was allometrically scaled bodyweight. Oral and IM bioavailabilities were 46 and 105%, respectively. For a 70 kg bodyweight, the population estimates were 7.6 L/h for clearance, 17.9 L for the volume of the central compartment, 2.5 L/h for the diffusional clearance and 16.6 L for the peripheral volume of distribution. Larger well‐designed studies are needed to describe the pharmacokinetics of TXA when given IM or as an oral solution before these can be recommended as alternatives to IV. 相似文献
10.